✦ LIBER ✦

Surrogate end-points for treatment trials of hepatitis B virus

✍ Scribed by P. D. Griffiths

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 55 KB
Volume: 20
Category: Article
ISSN: 1052-9276
DOI: 10.1002/rmv.662

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Utility of hepatitis C virus RNA determi

Utility of hepatitis C virus RNA determinations in hepatic tissue as an end point for interferon treatment of chronic hepatitis C

✍ Ahmet Gurakar; Stefano Fagiuoli; Hawazin Faruki; Nicola De Maria; Mujdat Balkan; 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 2 views

A total of 41 patients with chronic hepatitis C virus (HCV) defined as abnormal liver injury test results for 6 months or more and HCV RNA positivity in plasma were studied to determine if the liver might not be the only focus of HCV infection in individuals treated with interferon alfa (IFN-a). AU

Pretransplantation interferon treatment

Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B–related end-stage liver disease

✍ Patrick Marcellin; Didier Samuel; Jorge Areias; Marie-Anne Loriot; Jean-Louis Ar 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 603 KB

Orthotopic liver transplantation in patients with hepatitis B-related cirrhosis is commonly complicated by reinfection with the hepatitis B virus, with rapidly progressive liver disease and poor survival rate. We assessed the efficacy of prior therapy with recombinant interferon-a on the prevention

Treatment of hepatitis C virus–related c

Treatment of hepatitis C virus–related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment

✍ Dominique-Charles Valla; Michele Chevallier; Patrick Marcellin; Jean-Louis Payen 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

To examine the effects of interferon (IFN) therapy on clinical, biochemical, and histological features in patients with compensated hepatitis C virus (HCV)-related cirrhosis, we have conducted a randomized, controlled trial of IFN therapy versus observation. Eight centers included a total of 99 pati

A randomized controlled trial of thymosi

A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody—and hepatitis B virus DNA—positive chronic hepatitis B

✍ P Andreone; C Cursaro; A Gramenzi; C Zavaglia; I Rezakovic; E Altomare; R Severi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission

Lamivudine and interferon versus lamivud

Lamivudine and interferon versus lamivudine monotherapy for HBeAg-Positive hepatitis B treatment: A meta-analysis of randomized, controlled trials

✍ Dan Rudin 📂 Article 📅 2007 🏛 Springer Healthcare Communications 🌐 English ⚖ 225 KB

Predictors of response of U.S. veterans

Predictors of response of U.S. veterans to treatment for the hepatitis C virus

✍ Lisa I. Backus; Derek B. Boothroyd; Barbara R. Phillips; Larry A. Mole 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

The currently recommended treatment for hepatitis C virus (HCV) infection is pegylated interferon alfa (PEG-INF) and ribavirin, which can be difficult to tolerate. More information about predicting sustained virologic response (SVR) may allow more informed treatment decisions to be made. This retros